dasatinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
tyrosine kinase inhibitors 785 302962-49-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dasatinib
  • sprycel
  • spyrcel
  • BMS-354825
  • dasatinib hydrate
A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.
  • Molecular weight: 488.01
  • Formula: C22H26ClN7O2S
  • CLOGP: 2.71
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 3
  • TPSA: 106.51
  • ALOGS: -4.58
  • ROTB: 7
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 5.85 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2006 EMA BRISTOL-MYERS SQUIBB PHARMA EEIG
June 28, 2006 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1431.28 18.52 667 20102 92543 63375710
Cytogenetic analysis abnormal 339.31 18.52 75 20694 845 63467408
Adverse event 322.54 18.52 226 20543 67333 63400920
Drug resistance 316.35 18.52 153 20616 22780 63445473
Hospitalisation 257.35 18.52 217 20552 84864 63383389
Philadelphia chromosome positive 252.68 18.52 51 20718 355 63467898
Pulmonary oedema 246.63 18.52 177 20592 54696 63413557
Prescribed underdose 243.68 18.52 140 20629 29549 63438704
Malignant neoplasm progression 215.11 18.52 193 20576 81928 63386325
Acute lymphocytic leukaemia recurrent 213.20 18.52 62 20707 2207 63466046
Pericardial effusion 175.45 18.52 114 20655 29944 63438309
Fluid retention 163.63 18.52 144 20625 59542 63408711
Exposure via body fluid 156.11 18.52 37 20732 579 63467674
Nausea 146.64 18.52 608 20161 853863 62614390
Chylothorax 142.20 18.52 30 20739 266 63467987
Diarrhoea 139.43 18.52 530 20239 714836 62753417
Blast crisis in myelogenous leukaemia 133.59 18.52 32 20737 525 63467728
Death 132.86 18.52 342 20427 374039 63094214
Headache 115.69 18.52 460 20309 632781 62835472
Rash 111.83 18.52 419 20350 560452 62907801
Fatigue 99.16 18.52 559 20210 887469 62580784
Bone pain 93.69 18.52 102 20667 54539 63413714
Chronic myeloid leukaemia transformation 85.16 18.52 17 20752 111 63468142
Thrombocytopenia 82.39 18.52 164 20605 150993 63317260
Chronic myeloid leukaemia recurrent 79.99 18.52 18 20751 221 63468032
Blast cell crisis 72.49 18.52 14 20755 75 63468178
Pancytopenia 66.33 18.52 116 20653 96817 63371436
Infusion related reaction 64.46 18.52 4 20765 245517 63222736
Enterocolitis haemorrhagic 62.66 18.52 22 20747 1444 63466809
Acne 59.42 18.52 54 20715 23239 63445014
Pulmonary hypertension 56.25 18.52 65 20704 37058 63431195
Large granular lymphocytosis 55.99 18.52 13 20756 185 63468068
Leukaemia recurrent 53.09 18.52 19 20750 1319 63466934
Chronic myeloid leukaemia 52.86 18.52 22 20747 2296 63465957
Cytopenia 51.08 18.52 37 20732 11564 63456689
Haematotoxicity 50.88 18.52 34 20735 9342 63458911
Fall 49.40 18.52 34 20735 392300 63075953
Therapeutic product effect decreased 48.24 18.52 4 20765 193183 63275070
Pulmonary arterial hypertension 47.40 18.52 47 20722 22530 63445723
Platelet count decreased 47.22 18.52 112 20657 116010 63352243
Product dose omission issue 47.19 18.52 176 20593 234137 63234116
Bone marrow transplant 47.11 18.52 15 20754 727 63467526
Arthropathy 46.53 18.52 10 20759 234782 63233471
Myalgia 45.81 18.52 128 20641 146401 63321852
Condition aggravated 45.36 18.52 39 20730 402178 63066075
Acute graft versus host disease 44.84 18.52 24 20745 4404 63463849
Anaemia 44.56 18.52 202 20567 293228 63175025
Therapeutic response delayed 44.55 18.52 14 20755 650 63467603
Polymerase chain reaction positive 43.03 18.52 10 20759 143 63468110
Lymphoid tissue hyperplasia 40.41 18.52 10 20759 189 63468064
Exposure during pregnancy 39.45 18.52 3 20766 155544 63312709
Joint swelling 37.87 18.52 31 20738 327635 63140618
Aspiration pleural cavity 37.01 18.52 13 20756 854 63467399
Strongyloidiasis 35.90 18.52 14 20755 1234 63467019
Neutropenia 34.82 18.52 131 20638 174874 63293379
Nephrotic syndrome 34.61 18.52 22 20747 5554 63462699
Dyspnoea 34.19 18.52 348 20421 660965 62807288
Drug hypersensitivity 33.95 18.52 31 20738 310656 63157597
Enterococcal bacteraemia 33.78 18.52 14 20755 1445 63466808
Gene mutation identification test positive 33.24 18.52 8 20761 134 63468119
Emergency care examination 32.24 18.52 7 20762 72 63468181
Stem cell transplant 30.79 18.52 14 20755 1808 63466445
Graft versus host disease 30.76 18.52 22 20747 6741 63461512
Discomfort 29.55 18.52 9 20760 167365 63300888
Philadelphia positive chronic myeloid leukaemia 29.45 18.52 6 20763 44 63468209
Chronic graft versus host disease 29.15 18.52 16 20753 3086 63465167
Hepatitis chronic active 28.06 18.52 6 20763 57 63468196
Generalised oedema 27.91 18.52 30 20739 15788 63452465
Musculoskeletal stiffness 27.48 18.52 13 20756 184605 63283648
Therapy cessation 26.99 18.52 41 20728 30416 63437837
Pleurisy 26.66 18.52 22 20747 8318 63459935
Systemic candida 25.79 18.52 15 20754 3230 63465023
Alopecia 24.80 18.52 192 20577 337344 63130909
Acquired gene mutation 24.70 18.52 10 20759 973 63467280
Normal newborn 24.59 18.52 21 20748 8320 63459933
Colitis 23.27 18.52 50 20719 48478 63419775
Subdural haematoma 23.24 18.52 26 20743 14302 63453951
Tessellated fundus 23.16 18.52 5 20764 50 63468203
Full blood count decreased 23.01 18.52 35 20734 25989 63442264
Gene mutation 22.61 18.52 11 20758 1654 63466599
Periorbital oedema 22.49 18.52 17 20752 5667 63462586
Skin disorder 22.39 18.52 37 20732 29470 63438783
Cytomegalovirus colitis 21.64 18.52 12 20757 2360 63465893
Pericarditis 21.61 18.52 8 20761 131571 63336682
C-reactive protein increased 21.00 18.52 3 20766 94704 63373549
Cytomegalovirus enterocolitis 20.87 18.52 8 20761 673 63467580
Skin toxicity 20.67 18.52 15 20754 4699 63463554
Febrile neutropenia 20.57 18.52 85 20684 118364 63349889
Psoriatic arthropathy 20.06 18.52 3 20766 91517 63376736
Lymphocytosis 19.92 18.52 12 20757 2755 63465498
Leukaemia 19.85 18.52 14 20755 4194 63464059
Demyelinating polyneuropathy 19.80 18.52 8 20761 774 63467479
Vomiting 19.77 18.52 274 20495 559343 62908910
Intentional product use issue 19.32 18.52 88 20681 127804 63340449
Impaired healing 19.05 18.52 5 20764 102537 63365716
Blast cell proliferation 19.00 18.52 3 20766 3 63468250

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 1811.75 15.62 897 19289 80649 34856096
Adverse event 471.22 15.62 226 19960 18651 34918094
Drug resistance 442.11 15.62 240 19946 25687 34911058
Philadelphia chromosome positive 346.23 15.62 72 20114 304 34936441
Prescribed underdose 272.61 15.62 123 20063 8810 34927935
Hospitalisation 259.24 15.62 234 19952 56668 34880077
Malignant neoplasm progression 248.13 15.62 279 19907 87767 34848978
Cytogenetic analysis abnormal 247.20 15.62 62 20124 677 34936068
Chylothorax 229.09 15.62 59 20127 722 34936023
Drug intolerance 208.72 15.62 212 19974 59358 34877387
Blast crisis in myelogenous leukaemia 183.87 15.62 47 20139 557 34936188
Headache 153.06 15.62 349 19837 200286 34736459
Fluid retention 145.31 15.62 122 20064 26765 34909980
Pulmonary oedema 144.68 15.62 157 20029 47372 34889373
Acute lymphocytic leukaemia recurrent 143.14 15.62 57 20129 2987 34933758
Pericardial effusion 139.71 15.62 115 20071 24547 34912198
Fatigue 125.96 15.62 483 19703 370170 34566575
Death 88.22 15.62 457 19729 397592 34539153
Gene mutation 86.36 15.62 32 20154 1376 34935369
Large granular lymphocytosis 80.96 15.62 20 20166 204 34936541
Rash 80.87 15.62 297 19889 222455 34714290
Pulmonary hypertension 72.29 15.62 74 20112 20850 34915895
Acne 69.84 15.62 55 20131 11011 34925734
Acquired gene mutation 69.41 15.62 27 20159 1328 34935417
Diarrhoea 63.59 15.62 413 19773 389499 34547246
Chronic myeloid leukaemia transformation 56.22 15.62 14 20172 148 34936597
Bone pain 52.11 15.62 62 20124 20624 34916121
Hypotension 51.86 15.62 32 20154 221617 34715128
Thrombocytopenia 51.34 15.62 202 19984 156045 34780700
Chronic myeloid leukaemia 50.52 15.62 25 20161 2199 34934546
Pulmonary arterial hypertension 49.97 15.62 41 20145 8698 34928047
Loss of therapeutic response 49.15 15.62 17 20169 597 34936148
Philadelphia positive chronic myeloid leukaemia 48.70 15.62 12 20174 121 34936624
Blast cell proliferation 47.19 15.62 8 20178 6 34936739
Lymphoid tissue hyperplasia 44.47 15.62 10 20176 65 34936680
Aspiration pleural cavity 43.88 15.62 17 20169 827 34935918
Bone marrow transplant 40.01 15.62 17 20169 1051 34935694
Intentional product use issue 39.89 15.62 99 20087 59717 34877028
Chronic myeloid leukaemia recurrent 39.02 15.62 11 20175 193 34936552
Minimal residual disease 38.50 15.62 13 20173 424 34936321
Central nervous system neoplasm 37.54 15.62 9 20177 80 34936665
Gene mutation identification test positive 37.06 15.62 10 20176 148 34936597
Leukaemia recurrent 36.22 15.62 18 20168 1597 34935148
Pleurisy 35.38 15.62 26 20160 4695 34932050
Cytopenia 35.16 15.62 40 20146 12683 34924062
Therapy cessation 34.96 15.62 46 20140 16927 34919818
Condition aggravated 34.59 15.62 36 20150 192160 34744585
Oedema 34.03 15.62 79 20107 45662 34891083
Loss of CAR T-cell persistence 33.95 15.62 7 20179 28 34936717
Treatment failure 31.88 15.62 78 20108 46619 34890126
Myopathy toxic 31.16 15.62 12 20174 574 34936171
Bradycardia 30.04 15.62 4 20182 75414 34861331
Natural killer cell count increased 29.94 15.62 5 20181 3 34936742
Fall 28.28 15.62 46 20140 202839 34733906
Enterocolitis haemorrhagic 28.28 15.62 13 20173 970 34935775
Therapy change 27.81 15.62 19 20167 3058 34933687
Bone marrow disorder 26.60 15.62 15 20171 1720 34935025
Nausea 26.46 15.62 306 19880 339602 34597143
Blast cell crisis 26.44 15.62 7 20179 96 34936649
Drug clearance decreased 25.95 15.62 15 20171 1803 34934942
Chronic myeloid leukaemia (in remission) 25.83 15.62 4 20182 0 34936745
Second primary malignancy 25.62 15.62 27 20159 7859 34928886
Toxicity to various agents 25.58 15.62 48 20138 200314 34736431
Neoplasm recurrence 25.48 15.62 16 20170 2233 34934512
Anterior interosseous syndrome 25.37 15.62 5 20181 15 34936730
Clonal evolution 24.72 15.62 7 20179 125 34936620
Platelet count decreased 24.59 15.62 135 20051 119582 34817163
Hyperplasia 23.91 15.62 10 20176 594 34936151
Therapeutic response decreased 23.32 15.62 52 20134 29261 34907484
Right ventricular dysfunction 23.15 15.62 12 20174 1164 34935581
Chromosome analysis abnormal 23.01 15.62 7 20179 162 34936583
Skin disorder 22.33 15.62 33 20153 13522 34923223
Graft versus host disease 22.31 15.62 29 20157 10540 34926205
Product dose omission issue 21.96 15.62 131 20055 119580 34817165
Hepatotoxicity 21.65 15.62 42 20144 21443 34915302
Hyperkalaemia 20.88 15.62 7 20179 69382 34867363
Hyphaema 20.85 15.62 9 20177 578 34936167
Infusion related reaction 20.69 15.62 3 20183 53054 34883691
Acute kidney injury 20.24 15.62 99 20087 304889 34631856
Dyspnoea 20.13 15.62 317 19869 376465 34560280
Overdose 20.09 15.62 14 20172 91045 34845700
Cerebellar syndrome 19.83 15.62 14 20172 2374 34934371
Gelatinous transformation of the bone marrow 19.82 15.62 4 20182 14 34936731
Drug hypersensitivity 19.68 15.62 11 20175 80518 34856227
Bone neoplasm 19.47 15.62 7 20179 276 34936469
Myalgia 19.42 15.62 98 20088 84012 34852733
Central nervous system leukaemia 19.39 15.62 7 20179 279 34936466
Syncope 18.97 15.62 15 20171 91436 34845309
Peripheral arterial occlusive disease 18.89 15.62 20 20166 5854 34930891
Pancytopenia 18.66 15.62 106 20080 95051 34841694
Rectosigmoid cancer 18.41 15.62 6 20180 175 34936570
Subdural hygroma 18.02 15.62 7 20179 343 34936402
Loss of consciousness 17.86 15.62 13 20173 82654 34854091
Myeloproliferative neoplasm 17.75 15.62 8 20178 570 34936175
Hallucination 17.73 15.62 4 20182 51494 34885251
Allogenic bone marrow transplantation therapy 17.66 15.62 4 20182 27 34936718
B-cell small lymphocytic lymphoma 17.62 15.62 6 20180 201 34936544
Cytomegalovirus infection reactivation 17.48 15.62 18 20168 5100 34931645
Peripheral artery stenosis 17.46 15.62 9 20177 863 34935882
Cardiac arrest 17.29 15.62 18 20168 96141 34840604
Rhabdomyolysis 17.10 15.62 9 20177 68154 34868591
Oxygen saturation decreased 16.96 15.62 5 20181 53813 34882932
Coma 16.87 15.62 3 20183 45675 34891070
Tremor 16.56 15.62 14 20172 82573 34854172
Confusional state 16.30 15.62 37 20149 144123 34792622
Acute lymphocytic leukaemia refractory 16.26 15.62 5 20181 120 34936625
Bone development abnormal 16 15.62 4 20182 43 34936702
Eye swelling 15.98 15.62 24 20162 9971 34926774
Haemothorax 15.86 15.62 15 20171 3837 34932908
Deep vein thrombosis 15.81 15.62 9 20177 65239 34871506
Eyelid oedema 15.69 15.62 17 20169 5107 34931638
Subclavian artery stenosis 15.68 15.62 4 20182 47 34936698
Polymerase chain reaction positive 15.67 15.62 5 20181 136 34936609
Therapy non-responder 15.65 15.62 54 20132 39092 34897653

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pleural effusion 2698.34 15.38 1250 29825 144012 79569301
Drug resistance 531.23 15.38 280 30795 41933 79671380
Philadelphia chromosome positive 462.81 15.38 95 30980 595 79712718
Chylothorax 411.80 15.38 88 30987 687 79712626
Malignant neoplasm progression 357.57 15.38 346 30729 135644 79577669
Cytogenetic analysis abnormal 322.32 15.38 78 30997 1112 79712201
Pulmonary oedema 289.05 15.38 254 30821 88000 79625313
Pericardial effusion 283.18 15.38 193 30882 46044 79667269
Hospitalisation 272.77 15.38 253 30822 93983 79619330
Prescribed underdose 262.59 15.38 156 30919 29358 79683955
Adverse event 254.69 15.38 201 30874 60013 79653300
Blast crisis in myelogenous leukaemia 240.44 15.38 58 31017 815 79712498
Fluid retention 216.74 15.38 195 30880 69614 79643699
Acute lymphocytic leukaemia recurrent 208.69 15.38 76 30999 4648 79708665
Death 182.97 15.38 559 30516 565955 79147358
Headache 159.52 15.38 587 30488 653185 79060128
Rash 147.51 15.38 527 30548 577831 79135482
Large granular lymphocytosis 145.32 15.38 33 31042 350 79712963
Fatigue 141.68 15.38 724 30351 929003 78784310
Diarrhoea 134.31 15.38 686 30389 879803 78833510
Chronic myeloid leukaemia transformation 129.20 15.38 28 31047 235 79713078
Thrombocytopenia 120.44 15.38 297 30778 264962 79448351
Acne 106.87 15.38 87 30988 27103 79686210
Enterocolitis haemorrhagic 95.80 15.38 35 31040 2159 79711154
Gene mutation 92.43 15.38 36 31039 2650 79710663
Acquired gene mutation 91.51 15.38 34 31041 2199 79711114
Pulmonary arterial hypertension 91.46 15.38 81 30994 28285 79685028
Chronic myeloid leukaemia 84.88 15.38 37 31038 3627 79709686
Pulmonary hypertension 84.64 15.38 99 30976 47981 79665332
Bone pain 83.86 15.38 106 30969 55636 79657677
Philadelphia positive chronic myeloid leukaemia 76.51 15.38 17 31058 162 79713151
Nausea 74.29 15.38 630 30445 956566 78756747
Infusion related reaction 67.60 15.38 6 31069 230231 79483082
Fall 65.89 15.38 56 31019 487573 79225740
Condition aggravated 63.59 15.38 61 31014 501063 79212250
Platelet count decreased 62.37 15.38 192 30883 194472 79518841
Therapy cessation 62.24 15.38 75 31000 37487 79675826
Pancytopenia 62.23 15.38 173 30902 165572 79547741
Aspiration pleural cavity 60.38 15.38 23 31052 1594 79711719
Pleurisy 57.69 15.38 41 31034 10434 79702879
Blast cell crisis 56.98 15.38 13 31062 141 79713172
Bone marrow transplant 55.52 15.38 21 31054 1427 79711886
Leukaemia recurrent 51.49 15.38 24 31051 2750 79710563
Blast cell proliferation 50.33 15.38 8 31067 6 79713307
Cytopenia 49.96 15.38 50 31025 20333 79692980
Therapy change 47.92 15.38 32 31043 7367 79705946
Hypotension 47.70 15.38 61 31014 440256 79273057
Therapeutic product effect decreased 46.18 15.38 5 31070 163858 79549455
Febrile neutropenia 45.16 15.38 194 30881 230805 79482508
Arthropathy 43.84 15.38 8 31067 177103 79536210
Drug intolerance 42.15 15.38 209 30866 263910 79449403
Drug hypersensitivity 41.97 15.38 33 31042 298883 79414430
Full blood count decreased 41.92 15.38 52 31023 26767 79686546
Natural killer cell count increased 40.97 15.38 7 31068 12 79713301
Oedema 40.20 15.38 120 30955 119460 79593853
Lymphoid tissue hyperplasia 40.05 15.38 11 31064 264 79713049
Haematotoxicity 39.76 15.38 39 31036 15480 79697833
Musculoskeletal stiffness 39.05 15.38 10 31065 174998 79538315
Graft versus host disease 38.94 15.38 38 31037 14988 79698325
Chronic myeloid leukaemia recurrent 38.93 15.38 11 31064 294 79713019
Drug clearance decreased 38.79 15.38 21 31054 3306 79710007
Polymerase chain reaction positive 37.91 15.38 11 31064 324 79712989
Clonal evolution 37.15 15.38 10 31065 222 79713091
Cytomegalovirus colitis 37.11 15.38 23 31052 4662 79708651
Colitis 36.30 15.38 85 30990 73222 79640091
Chromosome analysis abnormal 36.29 15.38 10 31065 243 79713070
Lower respiratory tract infection 36.26 15.38 4 31071 129216 79584097
Gene mutation identification test positive 35.99 15.38 10 31065 251 79713062
Chronic myeloid leukaemia (in remission) 35.22 15.38 6 31069 10 79713303
Therapeutic response delayed 34.73 15.38 14 31061 1128 79712185
Toxicity to various agents 33.85 15.38 71 31004 421469 79291844
Mobility decreased 33.73 15.38 4 31071 122171 79591142
Mucosal inflammation 33.54 15.38 84 30991 75496 79637817
Central nervous system neoplasm 33.32 15.38 8 31067 110 79713203
Anaemia 32.75 15.38 290 30785 444725 79268588
Generalised oedema 32.38 15.38 43 31032 23666 79689647
Nephrotic syndrome 32.27 15.38 30 31045 11144 79702169
Enterococcal bacteraemia 32.01 15.38 18 31057 3050 79710263
Loss of CAR T-cell persistence 31.46 15.38 6 31069 24 79713289
Myalgia 31.10 15.38 149 30926 185492 79527821
Neutropenia 30.36 15.38 204 30871 287506 79425807
Skin disorder 29.74 15.38 50 31025 33893 79679420
Systemic candida 29.64 15.38 23 31052 6683 79706630
Glossodynia 29.50 15.38 3 31072 103334 79609979
Minimal residual disease 29.44 15.38 10 31065 497 79712816
Exposure during pregnancy 28.71 15.38 3 31072 101129 79612184
Intentional product use issue 28.36 15.38 126 30949 151986 79561327
Bone marrow failure 28.35 15.38 62 31013 51045 79662268
Joint swelling 28.21 15.38 43 31032 288603 79424710
Somnolence 28.09 15.38 31 31044 238950 79474363
Dyspnoea 28.07 15.38 479 30596 856546 78856767
Strongyloidiasis 28.03 15.38 18 31057 3880 79709433
Bone marrow disorder 27.98 15.38 17 31058 3326 79709987
Intentional overdose 27.98 15.38 4 31071 105956 79607357
Primary effusion lymphoma 27.83 15.38 6 31069 49 79713264
Oxygen saturation decreased 27.61 15.38 8 31067 129039 79584274
Emergency care examination 27.61 15.38 7 31068 122 79713191
Central nervous system leukaemia 27.10 15.38 9 31066 417 79712896
Periorbital oedema 27.09 15.38 24 31051 8378 79704935
Overdose 26.27 15.38 20 31055 184186 79529127
Anterior interosseous syndrome 25.65 15.38 5 31070 23 79713290
Skin toxicity 25.33 15.38 23 31052 8291 79705022
Acute graft versus host disease 25.02 15.38 25 31050 10142 79703171
Growth retardation 24.72 15.38 13 31062 1930 79711383
White blood cell count decreased 24.55 15.38 141 30934 188147 79525166
Therapeutic response decreased 24.29 15.38 69 31006 66784 79646529
C-reactive protein increased 24.16 15.38 10 31065 129017 79584296
Loss of therapeutic response 24.03 15.38 10 31065 874 79712439
Stem cell transplant 23.94 15.38 16 31059 3688 79709625
Hyperplasia 23.84 15.38 11 31064 1232 79712081
Cytomegalovirus enterocolitis 23.73 15.38 12 31063 1643 79711670
Syncope 23.71 15.38 21 31054 179428 79533885
Peripheral artery stenosis 23.28 15.38 11 31064 1300 79712013
Transplant 22.77 15.38 10 31065 998 79712315
Lymphocytosis 22.74 15.38 17 31058 4676 79708637
Second primary malignancy 22.71 15.38 28 31047 14322 79698991
Haemothorax 22.52 15.38 18 31057 5460 79707853
Cytomegalovirus infection reactivation 22.51 15.38 22 31053 8694 79704619
Multiple-drug resistance 22.31 15.38 22 31053 8786 79704527
Tessellated fundus 22.28 15.38 5 31070 50 79713263
Metabolic acidosis 22.06 15.38 3 31072 82526 79630787
Myopathy toxic 21.95 15.38 10 31065 1088 79712225
Bradycardia 21.62 15.38 13 31062 135544 79577769
Peripheral arterial occlusive disease 21.61 15.38 21 31054 8237 79705076
Discomfort 21.55 15.38 11 31064 125606 79587707
Splenomegaly 21.50 15.38 33 31042 20721 79692592
Asthma 21.49 15.38 13 31062 135082 79578231
Osteoarthritis 21.47 15.38 4 31071 87305 79626008
Leukaemia 21.28 15.38 18 31057 5907 79707406
Hypersensitivity 21.17 15.38 44 31031 262195 79451118
Inappropriate schedule of product administration 21.06 15.38 13 31062 133615 79579698
Right ventricular dysfunction 21.03 15.38 13 31062 2622 79710691
Hyphaema 20.52 15.38 9 31066 895 79712418
Psoriatic arthropathy 20.46 15.38 3 31072 77996 79635317
Product administered to patient of inappropriate age 20.21 15.38 17 31058 5536 79707777
Psoriasis 20.21 15.38 5 31070 89582 79623731
Intentional product misuse 20.17 15.38 6 31069 95159 79618154
Hepatitis chronic active 19.85 15.38 6 31069 204 79713109
Malaise 19.81 15.38 111 30964 489758 79223555
Acute lymphocytic leukaemia 19.73 15.38 16 31059 4953 79708360
Subdural haematoma 19.60 15.38 40 31035 31394 79681919
Product dose omission issue 19.57 15.38 164 30911 247373 79465940
Blast cell count increased 19.57 15.38 10 31065 1400 79711913
Eye swelling 19.33 15.38 36 31039 26432 79686881
Blood pressure increased 19.22 15.38 33 31042 211327 79501986
Hydrothorax 19.19 15.38 10 31065 1458 79711855
Chronic graft versus host disease 19.18 15.38 18 31057 6763 79706550
Therapy non-responder 19.16 15.38 79 30996 92226 79621087
Confusional state 19.05 15.38 62 31013 317935 79395378
Tremor 18.97 15.38 23 31052 170060 79543253
Pyrexia 18.88 15.38 370 30705 678339 79034974
Hepatotoxicity 18.65 15.38 53 31022 51299 79662014
Coma 18.52 15.38 8 31067 100641 79612672
Loss of consciousness 18.42 15.38 23 31052 167920 79545393
Cerebellar syndrome 18.36 15.38 16 31059 5464 79707849
Cardiac failure 18.28 15.38 113 30962 154729 79558584
Subdural hygroma 18.15 15.38 7 31068 502 79712811
Alopecia 18.14 15.38 153 30922 231202 79482111
Allogenic bone marrow transplantation therapy 17.56 15.38 4 31071 43 79713270
Sinusitis 17.34 15.38 31 31044 195470 79517843
Bacteraemia 17.28 15.38 39 31036 32785 79680528
Bone development abnormal 17.24 15.38 4 31071 47 79713266
Lipase increased 16.80 15.38 26 31049 16440 79696873
Balance disorder 16.45 15.38 9 31066 98848 79614465
Rhabdomyolysis 16.29 15.38 10 31065 103121 79610192
Cardiac tamponade 16.15 15.38 19 31056 9257 79704056
Impaired healing 16.07 15.38 7 31068 87648 79625665
Neoplasm malignant 15.87 15.38 37 31038 31773 79681540
Suicidal ideation 15.84 15.38 5 31070 76335 79636978
Fibromyalgia 15.71 15.38 3 31072 64337 79648976
Decreased appetite 15.69 15.38 203 30872 342215 79371098
Ventricular enlargement 15.69 15.38 7 31068 725 79712588
Drug reaction with eosinophilia and systemic symptoms 15.68 15.38 3 31072 64241 79649072
Cytogenetic abnormality 15.67 15.38 8 31067 1117 79712196
White blood cell count increased 15.58 15.38 64 31011 74569 79638744
Tumour lysis syndrome 15.56 15.38 31 31044 23908 79689405

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EA02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
BCR-ABL tyrosine kinase inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:149553 anticoronaviral drug

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Blastic phase chronic myeloid leukemia indication 413656006
Chronic phase chronic myeloid leukemia indication 413847001
Philadelphia chromosome-positive acute lymphoblastic leukemia indication 425688002
Philadelphia Chromosome Positive Chronic Myelocytic Leukemia indication
Chronic Myelocytic Leukemia Accelerated Phase indication
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Torsades de pointes contraindication 31722008
Body fluid retention contraindication 43498006
Chronic heart failure contraindication 48447003
Gastrointestinal hemorrhage contraindication 74474003
Left heart failure contraindication 85232009
Prolonged QT interval contraindication 111975006
Disease of liver contraindication 235856003 DOID:409
Edema contraindication 267038008
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Pericardial effusion contraindication 373945007 DOID:118
Ascites contraindication 389026000
Breastfeeding (mother) contraindication 413712001
Congenital long QT syndrome contraindication 442917000
Pleural Effusions contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.56 acidic
pKa2 7.72 Basic
pKa3 4.89 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Nov. 9, 2024 TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL May 9, 2025 PEDIATRIC EXCLUSIVITY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL Dec. 21, 2025 INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN COMBINATION WITH CHEMOTHERAPY
100MG SPRYCEL BRISTOL MYERS SQUIBB N021986 May 30, 2008 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
140MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
20MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
50MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
70MG SPRYCEL BRISTOL MYERS SQUIBB N021986 June 28, 2006 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY
80MG SPRYCEL BRISTOL MYERS SQUIBB N021986 Oct. 28, 2010 RX TABLET ORAL June 21, 2026 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 9.24 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase INHIBITOR Kd 9.68 CHEMBL CHEMBL
Tyrosine-protein kinase Lck Kinase INHIBITOR Kd 9.70 CHEMBL CHEMBL
Tyrosine-protein kinase Yes Kinase INHIBITOR Kd 9.52 CHEMBL CHEMBL
Tyrosine-protein kinase Fyn Kinase INHIBITOR Kd 9.10 CHEMBL CHEMBL
Ephrin type-A receptor 2 Kinase INHIBITOR Kd 9.07 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 9.20 CHEMBL CHEMBL
Tyrosine-protein kinase ABL1 Kinase INHIBITOR IC50 9.60 IUPHAR CHEMBL
Serine/threonine-protein kinase B-raf Kinase Kd 6.30 CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase Kd 5.49 CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase Kd 6.41 CHEMBL
Vascular endothelial growth factor receptor 1 Kinase Kd 5.30 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase Kd 5.54 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 9.24 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 9.33 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase Kd 5.85 CHEMBL
Myosin light chain kinase, smooth muscle Kinase Kd 7.14 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.41 CHEMBL
Tyrosine-protein kinase HCK Kinase INHIBITOR Kd 9.46 CHEMBL
Receptor tyrosine-protein kinase erbB-4 Kinase Kd 7.26 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Kinase IC50 4.52 CHEMBL
cAMP-dependent protein kinase catalytic subunit beta Kinase Kd 5.92 CHEMBL
Tyrosine-protein kinase JAK2 Kinase Kd 6 CHEMBL
Tyrosine-protein kinase SYK Kinase Kd 5.54 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.46 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 9 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 9.62 CHEMBL
Tyrosine-protein kinase Lyn Kinase INHIBITOR Kd 9.24 CHEMBL
Cytoplasmic tyrosine-protein kinase BMX Kinase Kd 8.85 CHEMBL
Serine/threonine-protein kinase Nek2 Kinase Kd 5.19 CHEMBL
LIM domain kinase 1 Kinase Kd 6.24 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 5.92 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 9.77 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.39 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 9.62 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 8.92 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.85 CHEMBL
Serine/threonine-protein kinase N1 Kinase Kd 6.45 CHEMBL
Protein kinase C theta type Kinase Kd 6.15 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 5.68 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.70 CHEMBL
Casein kinase I isoform epsilon Kinase Kd 5.82 CHEMBL
Tyrosine-protein kinase Fgr Kinase INHIBITOR Kd 9.30 CHEMBL
Aurora kinase A Kinase Kd 5.03 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 6.68 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 10.03 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 7.57 CHEMBL
Tyrosine-protein kinase FRK Kinase INHIBITOR Kd 9.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 7.35 CHEMBL
Mitogen-activated protein kinase kinase kinase 4 Kinase Kd 6.51 CHEMBL
Cyclin-G-associated kinase Kinase Kd 8.59 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 7.51 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 9.35 CHEMBL
Serine/threonine-protein kinase 4 Kinase Kd 5.42 CHEMBL
Activated CDC42 kinase 1 Kinase Kd 8.25 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6.14 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 9.16 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 9.47 CHEMBL
Activin receptor type-1B Kinase Kd 6.48 CHEMBL
Serine/threonine-protein kinase receptor R3 Kinase Kd 6.34 CHEMBL
Activin receptor type-1 Kinase Kd 6.21 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.54 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 1 Kinase Kd 6 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 2 Kinase Kd 5.85 CHEMBL
Tyrosine-protein kinase ITK/TSK Kinase IC50 6.64 CHEMBL
Protein-tyrosine kinase 6 Kinase Kd 8.11 CHEMBL
MAP kinase-activated protein kinase 2 Kinase Kd 6.27 CHEMBL
Tyrosine-protein kinase BTK Kinase Kd 8.85 CHEMBL
Tyrosine-protein kinase Tec Kinase Kd 7.89 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 9.41 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 6.17 CHEMBL
Non-receptor tyrosine-protein kinase TYK2 Kinase Kd 6.96 CHEMBL
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Kinase IC50 4.42 CHEMBL
Wee1-like protein kinase Kinase Kd 5.15 CHEMBL
Serine/threonine-protein kinase 25 Kinase Kd 5.47 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 7.35 CHEMBL
Tyrosine-protein kinase TXK Kinase Kd 8.68 CHEMBL
LIM domain kinase 2 Kinase Kd 7.07 CHEMBL
Serine/threonine-protein kinase 26 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.59 CHEMBL
Eukaryotic translation initiation factor 2-alpha kinase 4 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase SIK2 Kinase Kd 8.19 CHEMBL
Activin receptor type-2A Kinase Kd 6.68 CHEMBL
Activin receptor type-2B Kinase Kd 6.24 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 7.96 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.52 CHEMBL
Myotonin-protein kinase Kinase Kd 5.89 CHEMBL
Chaperone activity of bc1 complex-like, mitochondrial Kinase Kd 6.72 CHEMBL
Serine/threonine-protein kinase MRCK gamma Kinase Kd 5.92 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 6.01 CHEMBL
Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 3 Kinase Kd 6.19 CHEMBL
Aurora kinase B Kinase IC50 5.19 CHEMBL
Tyrosine-protein kinase Blk Kinase INHIBITOR Kd 9.68 CHEMBL
Bone morphogenetic protein receptor type-1A Kinase Kd 5.15 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.51 CHEMBL
Serine/threonine-protein kinase MRCK alpha Kinase Kd 5.70 CHEMBL
Serine/threonine-protein kinase MRCK beta Kinase Kd 5.68 CHEMBL
Serine/threonine-protein kinase PAK 4 Kinase Kd 6.13 CHEMBL
Serine/threonine-protein kinase SIK1 Kinase Kd 8.41 CHEMBL
Tyrosine-protein kinase Srms Kinase INHIBITOR Kd 7.89 CHEMBL
Dual specificity testis-specific protein kinase 1 Kinase Kd 7.48 CHEMBL
TGF-beta receptor type-1 Kinase Kd 6.64 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 8.39 CHEMBL
Ephrin type-B receptor 3 Kinase Kd 8.16 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 2 Kinase Kd 5.89 CHEMBL
Misshapen-like kinase 1 Kinase Kd 6.37 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 10.41 CHEMBL
Mitogen-activated protein kinase kinase kinase 13 Kinase Kd 5.28 CHEMBL
Mitogen-activated protein kinase kinase kinase 2 Kinase Kd 6.85 CHEMBL
Mitogen-activated protein kinase kinase kinase 3 Kinase Kd 6.55 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.43 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.64 CHEMBL
Serine/threonine-protein kinase ULK3 Kinase Kd 5.34 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase 35 Kinase Kd 6.11 CHEMBL
Receptor tyrosine-protein kinase erbB-3 Kinase Kd 7.74 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.90 CHEMBL
Serine/threonine-protein kinase SIK3 Kinase Kd 7.55 CHEMBL
Wee1-like protein kinase 2 Kinase Kd 6.70 CHEMBL
Bone morphogenetic protein receptor type-1B Kinase Kd 7.28 CHEMBL
Serine/threonine-protein kinase SBK1 Kinase Kd 5.92 CHEMBL
Serine/threonine-protein kinase VRK2 Kinase Kd 5.49 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 5.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 8.48 CHEMBL
Serine/threonine-protein kinase Nek11 Kinase Kd 6.33 CHEMBL
MAP kinase p38 Kinase IC50 7 CHEMBL
Dual specificity mitogen-activated protein kinase kinase; MEK1/2 Kinase IC50 5.77 CHEMBL
Bcr/Abl fusion protein Kinase IC50 9.10 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 6.19 CHEMBL
Myelin transcription factor 1 Transcription factor IC50 7.20 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.84 CHEMBL
Transthyretin Secreted Kd 5.51 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.70 CHEMBL
Epidermal growth factor receptor Kinase Kd 7.10 CHEMBL
Serine/threonine-protein kinase mTOR Kinase IC50 4.46 CHEMBL
Breakpoint cluster region protein Kinase Kd 8.30 CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase Kd 6.24 CHEMBL
Proto-oncogene tyrosine-protein kinase LCK Kinase Ki 10.19 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase Kd 7.96 CHEMBL
Tubulin alpha-1A chain Structural Kd 7.26 CHEMBL
Tyrosine-protein kinase Blk Kinase IC50 8.10 CHEMBL
Quinolone resistance protein NorA Transporter IC50 4.94 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.19 CHEMBL

External reference:

IDSource
4025488 VUID
N0000179780 NUI
D03658 KEGG_DRUG
475342 RXNORM
4025488 VANDF
C1455147 UMLSCUI
CHEBI:70839 CHEBI
1N1 PDB_CHEM_ID
CHEMBL1421 ChEMBL_ID
D000069439 MESH_DESCRIPTOR_UI
DB01254 DRUGBANK_ID
5678 IUPHAR_LIGAND_ID
RBZ1571X5H UNII
3062316 PUBCHEM_CID
21648 MMSL
83173 MMSL
d05831 MMSL
011616 NDDF
422756008 SNOMEDCT_US
423658008 SNOMEDCT_US
863127-77-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0524 TABLET 70 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0527 TABLET 20 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0528 TABLET 50 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0852 TABLET 100 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0855 TABLET 80 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 0003-0857 TABLET 140 mg ORAL NDA 27 sections
SPRYCEL HUMAN PRESCRIPTION DRUG LABEL 1 54868-5759 TABLET 70 mg ORAL NDA 28 sections